These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 7621422)

  • 1. Combination adriamycin and suramin induces apoptosis in bcl-2 expressing prostate carcinoma cells.
    Tu SM; McConnell K; Marin MC; Campbell ML; Fernandez A; von Eschenbach AC; McDonnell TJ
    Cancer Lett; 1995 Jul; 93(2):147-55. PubMed ID: 7621422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
    Ray S; Almasan A
    Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apoptosis suppression by bcl-2 is correlated with the regulation of nuclear and cytosolic Ca2+.
    Marin MC; Fernandez A; Bick RJ; Brisbay S; Buja LM; Snuggs M; McConkey DJ; von Eschenbach AC; Keating MJ; McDonnell TJ
    Oncogene; 1996 Jun; 12(11):2259-66. PubMed ID: 8649765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells.
    Haldar S; Chintapalli J; Croce CM
    Cancer Res; 1996 Mar; 56(6):1253-5. PubMed ID: 8640809
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis in malignant and camptothecin-resistant human cells.
    Chatterjee D; Wyche JH; Pantazis P
    Ann N Y Acad Sci; 1996 Dec; 803():143-56. PubMed ID: 8993507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
    Munshi A; McDonnell TJ; Meyn RE
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
    Ogura T; Tanaka Y; Tamaki H; Harada M
    Int J Oncol; 2016 Jun; 48(6):2330-8. PubMed ID: 27082738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergistic and antagonistic effects of cytotoxic and biological agents on the in vitro antitumour effects of suramin.
    Lopez Lopez R; van Rijswijk RE; Wagstaff J; Pinedo HM; Peters GJ
    Eur J Cancer; 1994; 30A(10):1545-9. PubMed ID: 7833116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: the role of apoptosis.
    Sklar GN; Eddy HA; Jacobs SC; Kyprianou N
    J Urol; 1993 Nov; 150(5 Pt 1):1526-32. PubMed ID: 8411447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
    Karaca B; Degirmenci M; Ozveren A; Atmaca H; Bozkurt E; Karabulut B; Sanli UA; Uslu R
    Cancer Chemother Pharmacol; 2015 Jun; 75(6):1273-80. PubMed ID: 25925002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of bcl-2 and the progression of human and rodent prostatic cancers.
    Furuya Y; Krajewski S; Epstein JI; Reed JC; Isaacs JT
    Clin Cancer Res; 1996 Feb; 2(2):389-98. PubMed ID: 9816182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
    Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
    Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic chemosensitization and inhibition of progression to androgen independence by antisense Bcl-2 oligodeoxynucleotide and paclitaxel in the LNCaP prostate tumor model.
    Leung S; Miyake H; Zellweger T; Tolcher A; Gleave ME
    Int J Cancer; 2001 Mar; 91(6):846-50. PubMed ID: 11275990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
    Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
    Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector.
    Murphy AM; Sheahan BJ; Atkins GJ
    Int J Cancer; 2001 Nov; 94(4):572-8. PubMed ID: 11745446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells.
    Biroccio A; Del Bufalo D; Fanciulli M; Bruno T; Zupi G; Floridi A
    Int J Cancer; 1999 Jul; 82(1):125-30. PubMed ID: 10360831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.
    Berchem GJ; Bosseler M; Sugars LY; Voeller HJ; Zeitlin S; Gelmann EP
    Cancer Res; 1995 Feb; 55(4):735-8. PubMed ID: 7850782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells.
    Dorai T; Perlman H; Walsh K; Shabsigh A; Goluboff ET; Olsson CA; Buttyan R
    Int J Cancer; 1999 Sep; 82(6):846-52. PubMed ID: 10446452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 proto-oncogene expression in human breast cancer cells.
    Teixeira C; Reed JC; Pratt MA
    Cancer Res; 1995 Sep; 55(17):3902-7. PubMed ID: 7641210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
    Song S; Wientjes MG; Walsh C; Au JL
    Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.